| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaNCT03108495 | IOVA | Phase 2 | Terminated | 2025-08-22Actual |
| Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaNCT03110562 | KPTI | Phase 3 | Completed | 2020-02-18Actual |
| 12-Week Open-Label Extension Study of TNX-102 SL in PTSD PatientsNCT03110575 | Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | 2018-07-27Actual |
| A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804NCT03118570 | RARE | Phase 2 | Completed | 2019-10-01Actual |
| Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586 | ACAD | Phase 3 | Terminated | 2024-04-30Actual |
| AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT03127514 | AMLX | Phase 2 | Completed | 2019-09-25Actual |
| The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic CystitisNCT03129126 | Lipella Pharmaceuticals, Inc. | Phase 2 | Completed | 2023-08-21Actual |
| SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.NCT03131154 | ALDX | Phase 3 | Completed | 2019-04-19Actual |
| A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye SyndromeNCT03162783 | ALDX | Phase 2 | Completed | 2017-07-06Actual |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsNCT03175224 | APLM | Phase 2 | Recruiting | 2026-03-30Estimated |
| Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyNCT03179631 | PTC Therapeutics | Phase 3 | Completed | 2022-03-05Actual |
| Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)NCT03180684 | Inovio Pharmaceuticals | Phase 2 | Completed | 2020-07-23Actual |
| Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for HemodialysisNCT03183245 | HUMA | Phase 3 | Completed | 2024-04-22Actual |
| REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)NCT03185013 | Inovio Pharmaceuticals | Phase 3 | Completed | 2020-07-08Actual |
| Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel DiseaseNCT03201445 | LKFT | Phase 2 | Terminated | 2020-11-20Actual |
| Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757 | Alkermes, Inc. | Phase 3 | Completed | 2023-09-06Actual |
| Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeNCT03205995 | Omeros Corporation | Phase 3 | Terminated | 2021-02-02Actual |
| Addressing Dementia Via Agitation-Centered EvaluationNCT03226522 | AXSM | Phase 2, Phase 3 | Completed | 2020-04-17Actual |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667 | IBRX | Phase 2 | Active not recruiting | 2029-08-31Estimated |
| Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAXNCT03232567 | ALT | Phase 2 | Completed | 2018-03-07Actual |
| A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)NCT03246529 | BLRX | Phase 3 | Active not recruiting | 2020-12-22Actual |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCNCT03257033 | RenovoRx | Phase 3 | Active not recruiting | 2027-06Estimated |
| Study of SPR001 in Adults With Classic Congenital Adrenal HyperplasiaNCT03257462 | Spruce Biosciences | Phase 2 | Completed | 2019-03-02Actual |
| Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion BurdenNCT03263091 | Kyntra Bio | Phase 3 | Terminated | 2023-03-09Actual |
| p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246NCT03268382 | Aprea Therapeutics | Phase 2 | Completed | 2019-07-10Actual |
| A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney DiseaseNCT03270956 | Prokidney | Phase 2 | Completed | 2022-11-17Actual |
| Safety and Efficacy of Repeated Administrations of NurOwn® in ALS PatientsNCT03280056 | Brainstorm-Cell Therapeutics | Phase 3 | Completed | 2020-09-29Actual |
| ONC201 in Adults With Recurrent H3 K27M-mutant GliomaNCT03295396 | Jazz Pharmaceuticals | Phase 2 | Terminated | 2022-12-31Actual |
| Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza ANCT03315104 | Emergent BioSolutions | Phase 2 | Completed | 2019-06-17Actual |
| Long-Term Safety Study of TafenoquineNCT03320174 | 60 Degrees Pharmaceuticals LLC | Phase 2 | Completed | 2021-07-13Actual |
Trial details
- Registry ID
- NCT03108495
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03110562
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03110575
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03118570
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03121586
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03127514
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03129126
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03131154
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03162783
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03175224
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03179631
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03180684
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03183245
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03185013
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03201445
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03201757
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03205995
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03226522
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT03228667
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03232567
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03246529
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03257033
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03257462
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03263091
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03268382
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03270956
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03280056
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03295396
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03315104
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03320174
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.